News
PSMA and Beyond 2025 CAR-T and Bispecific antibodies targeting PSMA, Poseida trial, neuroendocrine prostate cancer, STEAP-1.
AUA 2025 Tokai Urologic Oncology Research Study (TOURS) database study, tyrosine kinase inhibitors (TKIs), immunotherapy (IO), advanced renal cell carcinoma (RCC).
AUA 2025, Metastatic Renal Cell Carcinoma (mRCC), Maximal Evaluable Lesion Size in Patients with Metastatic Renal Cell Carcinoma, Nivolumab plus Ipilimumab Combination Therapy, nivolumab, ipilimumab, ...
PSMA and Beyond 2025 CA-IX in renal cell cancer (RCC), ZIRCON, kidney cancer, stage migration for RCC, REDECT trial, renal mass biopsy, girentuximab.
Andrea Miyahira hosts Marina Sharifi about a multiomic profiling study of metastatic castration-resistant prostate cancer using circulating tumor cells, ctDNA, and RNA sequencing.
The prevalence of kidney stone disease and associated events is rising, with modern surgical approaches emphasizing minimally invasive techniques like ambulatory percutaneous nephrolithotomy (PCNL).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback